Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Center
Department of Biotechnology
Eligibility
Inclusion criteria
Inclusion criteria: Adult Patients with early-stage breast cancer undergoing biopsy if age less than 50 years. Adult Patients 18-65 years of age with metastatic breast cancer that is histologically proven to be triple negative. Adult Patients with early-stage breast cancer undergoing biopsy if age less than 50 years.
Exclusion criteria
Exclusion criteria: 1. Patients with hormone receptor positive or HER 2 positive breast cancer 2. Patients who had received two or more lines of chemotherapy in metastatic setting
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To study the expression of CD1d in commercially available TNBC cell lines, TNBC patient tumour sections from early untreated, post-chemotherapy treated & metastatic patients. 2. To study the anti-tumor activity of invariant natural killer T (iNKT) cells, first in preclinical TNBC cell lines, patient derived cell lines & then in animal xenograft model. 3. To produce peripheral monocyte-derived APCs & ex-vivo expanded iNKT cells in a cellular GMP facility. . To prepare a Clinical Trial for evaluation of the safety and feasibility of iNKT cell infusion in metastatic triple negative breast cancer patients.Timepoint: 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Preparation of activated iNKT cells from peripheral bloodTimepoint: 3 years | — |
Countries
India
Contacts
Public ContactDr Seema Gulia
Tata Memorial Centre
Outcome results
None listed